HC Wainwright Issues Pessimistic Forecast for COLL Earnings

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Research analysts at HC Wainwright cut their Q1 2025 earnings estimates for shares of Collegium Pharmaceutical in a note issued to investors on Monday, March 24th. HC Wainwright analyst O. Livnat now expects that the specialty pharmaceutical company will post earnings per share of $1.20 for the quarter, down from their prior estimate of $1.29. HC Wainwright currently has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Collegium Pharmaceutical’s current full-year earnings is $5.62 per share. HC Wainwright also issued estimates for Collegium Pharmaceutical’s Q2 2025 earnings at $1.48 EPS.

A number of other research analysts have also recently commented on COLL. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research note on Friday, January 10th. Piper Sandler reduced their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $43.60.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ:COLL opened at $30.15 on Wednesday. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical has a 12 month low of $27.28 and a 12 month high of $42.29. The company has a market capitalization of $949.30 million, a price-to-earnings ratio of 13.00 and a beta of 0.99. The firm’s 50-day moving average is $30.57 and its 200 day moving average is $32.54.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. The firm had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%.

Insider Buying and Selling

In other news, CFO Colleen Tupper sold 1,949 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00. Following the transaction, the chief financial officer now owns 177,195 shares of the company’s stock, valued at approximately $5,315,850. This represents a 1.09 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Shirley R. Kuhlmann sold 27,500 shares of the firm’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the transaction, the executive vice president now owns 119,184 shares in the company, valued at approximately $3,937,839.36. This represents a 18.75 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 109,193 shares of company stock valued at $3,243,594 over the last quarter. 3.98% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

Hedge funds and other institutional investors have recently modified their holdings of the business. Nisa Investment Advisors LLC boosted its position in Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 316 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Collegium Pharmaceutical by 1.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,221 shares of the specialty pharmaceutical company’s stock worth $522,000 after purchasing an additional 339 shares during the last quarter. AlphaQuest LLC boosted its position in Collegium Pharmaceutical by 3.0% during the fourth quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company’s stock valued at $366,000 after purchasing an additional 374 shares in the last quarter. Foundry Partners LLC grew its stake in Collegium Pharmaceutical by 2.4% in the fourth quarter. Foundry Partners LLC now owns 16,162 shares of the specialty pharmaceutical company’s stock valued at $463,000 after purchasing an additional 381 shares during the last quarter. Finally, Gallacher Capital Management LLC raised its holdings in Collegium Pharmaceutical by 3.3% in the fourth quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company’s stock worth $417,000 after purchasing an additional 470 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.